Abstract
Vascular endothelial growth factor (VEGF) is one of the most potent factors for stimulating angiogenesis, an essential process required for expansion of primary tumour and dissemination of malignant cells. To investigate the possible role of VEGF in facilitating metastasis of prostate cancer via stimulating angiogenesis, we have used Northern and slot blotting, reverse transcription polymerase chain reaction, nucleotide sequence analysis and enzyme-linked immunosorbent assay to compare the VEGF expression in series of human and rat cell lines with either benign or malignant characteristics. We have also employed the chick chorioallantoic membrane (CAM) assay to measure the angiogenic activity of the VEGF derived from both benign and malignant cells. The level of VEGF mRNA expressed in the seven malignant human and rat cell lines is 3.5- to 10-fold higher than that expressed in the benign cell lines. The three metastatic variants, generated by transfection of a benign cell line with DNA extracted from prostate carcinoma cells, expressed 2.5 to 5 times more VEGF mRNA than their parental benign cells. While VEGF 121 and 165 were predominantly expressed by both the benign and malignant cells, the transcript representing VEGF 189 isoform was only detected in the malignant cells. At protein level, three human malignant cell lines produced more VEGF (2.7–7.9 ng ml–1) than the benign cell line (1.3 ng ml–1). CAM assay detected a VEGF-dependent angiogenic activity in the medium from malignant cells, but only a relatively weak VEGF-independent activity in the medium from benign cells. These results demonstrated that malignant cells did over-express VEGF and only the VEGF derived from malignant cells was angiogenically active. Thus, we suggest that the VEGF produced by malignant cells might play an important role in facilitating metastasis of prostatic cancer. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alwine JC, Kemp DJ and Stark G (1977) Methods for the detection of specific RNAs in agarose gel by transfer to diazobenzymethyl-paper and hybridization with DNA probes. Proc Natl Acad Sci USA 12: 5350–5354
Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ and Dinney CPN (1999) Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpression vascular endothelial growth factor. Clin Cancer Res 5: 783–789
Battegay EJ (1995) Angiogenesis-mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73: 333–346
Berthon P, Cussenot O, Hopwood I, Leduc A and Maitland NJ (1995) Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells – differentiation pattern of non-tumorigenic cell-lines. Int J Oncol 6: 333–343
Connolly JM and Rose DP (1998) Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 160: 932–936
Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D and Harris AL (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281–5285
Cussenot O, Berthon P, Berger R, Mowszowixz I, Faille A, Hojman F, Teillac P, Leduc A and Calvo F (1991) Immortalization of human adult normal prostatic epithelial-cells by Liposomes containing Large T-SV40 gene. J Urol 146: 881–886
Cussenot O, Berthon P, Cochandpriollet S, Maitland NJ and Leduc A (1994) Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue-sections. Exp Cell Res 214: 83–92
Deshmukh N, Scotson J, Dodson AR, Ke Y and Foster CS (1997) Differential expression of acidic- and basic-FGF in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol 80: 869–874
Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C and Van Oosterom AT (1996) Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7: 843–848
Dunnington DJ, Kim U, Hughes CM, Monaghan P, Ormerod J and Rudland PS (1983) Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 71: 1227–1240
Duque JLF, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D and Freeman MR (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urol 54: 523–527
Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertson PC, Laudone VP and Kreutzer DL (1997) Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157: 2329–2333
Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertson PC, Laudone VP and Kreutzer DL (1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by protate cancer cells. Urol 51: 161–167
Foster CS (1990) Predictive factors in prostatic hyperplasia and neoplasia. Hum Pathol 21: 575–577
Foster CS and Abel PD (1992) Clinical and molecular techniques for diagnosis and monitoring of prostatic cancer. Hum Pathol 23: 395–401
Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain R and Seed B (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715–725
Geller J (1995) Approach to chemoprevention of prostate-cancer. J Clin Endocrinol Met 80: 717–719
Haggstrom S, Wikstrom P, Bergh A and Damber JE (1998) Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 36: 71–79
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Miranol EA and Murphy GP (1983) LNcap model of human prostatic-carcinoma. Cancer Res 43: 1809–1818
Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806–1814
Isaacs JT, Issaacs WB, Feitz WFJ and Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell-lines and their use in developing methods for predicting metastatic abilities of prostatic cancer. Prostate 9: 261–281
Jackson MW, Bentel JM and Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323–2328
Kaighn ME, Narayan S, Ohnuki Y, Lechner JF and Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16–23
Ke Y, Beesley C, Smith Barraclough R, Rudland PS and Foster CS (1998) Generation of metastatic variants by transfection of a rat non-metastatic epithelial cell line with genomic DNA from rat prostatic carcinoma cells. Br J Cancer 77: 287–296
Kraft A, Weindel K, Ochs A, Marth C, Zmiji J, Schumacher P, Unger C, Marme D and Gastl G (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseases. Cancer 85: 178–187
Liotta LA, Steeg PS and Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an inbalance of positive and negative regulation. Cell 64: 327–336
Melnyk O, Zimmerman M, Kim KJ and Shuman M (1999) Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastasis in a pre-clinical model. J Urol 161: 960–963
Molica S, Vitelli G, Levato D, Gandolfo GM and Liso V (1999) Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 107: 605–610
Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavaky I, Keshet E and Neufeld G (1997) VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151–7158
Salven P, Maenpaa H, Orpana A, Alitalo K and Joensuu H (1997) Serum VEGF is often elevated in disseminated cancer. Clin Cancer Res 6: 647–651
Shima DT, Adamis AP, Ferrara N, Yeo KT, Allende R, Folkman J and Damore PA (1995) Hypoxic induction of endothelial-cell growth-factors in retinal cells – identification and characterization of vascular endothelial growth-factor (VEGF) as the mitogen. Mol Med 2: 64–71
Stephan CC and Brock TA (1996) Vascular endothelial growth factor, a multifunctional polypeptide. Puerto Rico Health Sci J 15: 169–178
Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274–281
Tischer E, Mitcher R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA (1991) The human gene for vascular endothelial growth factor, multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947–11954
Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N and Nakamura M (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is associated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77: 998–1002
Weidner N (1995) Intratumor microvessel density as prognostic factor in cancer. Am J Pathol 147: 9–15
West DC, Hampson IN, Arnold F and Kumar S (1985) Angiogenesis induced by degradation products of hyaluronic-acid. Science 228: 1324–1326
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Chen, H., Treweeke, A., Ke, Y. et al. Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells. Br J Cancer 82, 1694–1701 (2000). https://doi.org/10.1054/bjoc.2000.1122
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1122